- Full-year 2019 Total Revenues Increased 14% to $1.7 billion
- 17% Increase in Net Product Revenues from Products Marketed by BioMarin to $1.6 billion in Full-year 2019
- 2020 Full-year Total Revenue Growth Expected to be Between 14% and 20%
- For the Full-year 2020 BioMarin Expects for the First Time to be Profitable on a GAAP Basis
- U.S. and European Marketing Submissions for Valoctocogene Roxaparvovec for Severe Hemophilia A Accepted by FDA and EMA under Priority Review and Accelerated Assessment, Respectively; Approval Decisions Expected in Second Half of 2020
- Phase 3 Study with Vosoritide for Achondroplasia Demonstrated Highly Statistically Significant Increase (p
